SOLOSCRIPT
Su - Non-Final Action - Mailed
Status timeline
- 3 Feb 2025Application filedNew Application Entered
- 14 Jul 2025Assigned to an examining attorneyAssigned To Examiner
- 14 Jul 2025Office action issuedNon-Final Action Written
- 6 Sep 2025Response to office action filedTeas Response To Office Action Received
- 10 Sep 2025Approved for publicationApproved For Pub - Principal Register
- 7 Oct 2025Published for oppositionPublished For Opposition
- 2 Dec 2025Notice of allowance issued — statement of use requiredNoa E-Mailed - Sou Required From Applicant
- 8 May 2026Statement of use filedTeas Statement Of Use Received
- 4 Aug 2026Office action issuedNon-Final Action Written
All 22 USPTO events
| 2026-08-04 | Non-Final Action Written |
| 2026-08-04 | Non-Final Action E-Mailed |
| 2026-08-04 | Notification Of Non-Final Action E-Mailed |
| 2026-07-18 | Case Assigned To Intent To Use Paralegal |
| 2026-07-18 | Statement Of Use Processing Complete |
| 2026-05-08 | Teas Statement Of Use Received |
| 2026-05-08 | Use Amendment Filed |
| 2025-12-02 | Noa E-Mailed - Sou Required From Applicant |
| 2025-10-07 | Published For Opposition |
| 2025-10-07 | Official Gazette Publication Confirmation E-Mailed |
| 2025-10-01 | Notification Of Notice Of Publication E-Mailed |
| 2025-09-10 | Approved For Pub - Principal Register |
| 2025-09-07 | Teas/Email Correspondence Entered |
| 2025-09-06 | Teas Response To Office Action Received |
| 2025-09-06 | Correspondence Received In Law Office |
| 2025-07-14 | Assigned To Examiner |
| 2025-07-14 | Non-Final Action Written |
| 2025-07-14 | Non-Final Action E-Mailed |
| 2025-07-14 | Notification Of Non-Final Action E-Mailed |
| 2025-07-03 | New Application Office Supplied Data Entered |
| 2025-02-03 | New Application Entered |
| 2025-02-03 | Application Filing Receipt Mailed |
Goods & services
Class 1 Chemicals
RNA polymerase in the nature of enzymes for use in the manufacture of pharmaceutical preparations, medical and scientific research, and development of medical treatments; Biotechnology reagents for scientific or medical research use, namely, RNA polymerase and RNA polymerase formulations; Enzymes for use in the preparation and creation of DNA and RNA for use in the manufacture of pharmaceutical preparations, medical and scientific research, and development medical treatments
First use anywhere 26 Sep 2024 · First use in commerce 26 Sep 2024
Class 5 Pharmaceuticals & supplements
Therapeutic RNA, namely, nucleic acid sequences and chemical reagents for medical and veterinary purposes; Reagents for medical or veterinary use
First use anywhere 26 Sep 2024 · First use in commerce 26 Sep 2024
Class 40 Materials treatment
Custom manufacturing of pharmaceuticals; Custom manufacture of therapeutic drugs, in the nature of therapeutics comprising DNA, RNA, genes, and oligonucleotides; Providing custom manufacture of mRNA and long RNA for others, namely, custom synthesis and combinations of mRNA and long RNA molecules; Custom manufacture of oligonucleotides and RNAs for use in genetic research, pharmaceutical therapies, medical research and treatment of various conditions and disorders
First use anywhere 26 Sep 2024 · First use in commerce 26 Sep 2024
Source & freshness
Source: USPTO Trademark Applications bulk data. This record was last updated by the USPTO file dated 4 Aug 2026; the index was built on 20 Nov 2026 and covers USPTO data through 31 Aug 2026. Open the official USPTO record (TSDR) → If the two differ, the USPTO record is correct.